On 15 February, 2021, the paper Discrete SARS-CoV-2 antibody titers track with functional humoral stability was accepted for publication by the prestigious journal Nature — interesting not only for being a large-cohort study on COVID-19 reinfection, but for the presence of one of its coauthors: one Elon Reeve Musk. According to reporting, Musk — concerned in April 2020 with maintaining the schedule for the SpaceX crewed launch in May and wanting to make sure that an outbreak wouldn’t set back plans — contacted academic researchers and worked with them to set up an antibody testing research programme. Over 4,000 SpaceX employees volunteered and were provided with periodic free testing at work to look for infection and monitor previously-infected people for reinfection. The programme gave SpaceX an advance heads up about upcoming threats, such as the growing wave in Texas in June, and continues to this day, with a new focus on mutant COVID strains.
The primary results of the study? Past infection provides a strong, although not perfect, barrier to reinfection; the level of antibodies strongly indicate the level of risk of reinfection; and this bodes well for vaccines, which tend to result in much higher antibody levels than infection.
Read more of this story at Slashdot.